ReviewViruses2022
RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein.
Review in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Emergence and Global Circulation of the HRSV BA Variant with a 7-AA Extension in the G Protein Under Persistent BA Predominance - Global, 1996-2025.China CDC weekly · 2026Article
- Target-Based Antiviral Drug Development Against Human Respiratory Viruses.Pathogens (Basel, Switzerland) · 2026Review
- A comprehensive look at Respiratory Syncytial Virus (RSV): from pathogenesis to prevention.Tropical diseases, travel medicine and vaccines · 2026Review
- Research progress on the current status of respiratory pathogen infections and their detection methods.Frontiers in microbiology · 2026Review
- Post-Translational Modifications in Respiratory Virus Infection: Recent Insights into the Development of In Vitro Models.International journal of molecular sciences · 2025Review
- Molecular Surveillance RevealsVaccines · 2025Article
- Respiratory syncytial virus positivity, seasonal trends and risk factors among children under five with acute respiratory infection in Western Democratic Republic of Congo, 2022-2023.BMC infectious diseases · 2025Article
- RSV Vaccines: Targeting Prefusion F and G Proteins from Structural Design to Clinical Application.Vaccines · 2025Review
- Attenuate host susceptibility to respiratory virus invasion by inhibiting interactions between host proteins SLC16A3 and AP1G1.Microbiology spectrum · 2025Article
- Intratracheal instillation of RSV is superior to intranasal inoculation as a model method inducing critical immune cell infiltration.Scientific reports · 2025Article
- Epidemiology and genetic diversity of respiratory syncytial virus in adults 50 years and older with acute respiratory infections in Accra, Ghana.BMC infectious diseases · 2025Article
- Passive Immunization in the Prevention and Treatment of Viral Infections.European journal of immunology · 2025Review
- Layer-by-Layer Microparticle Vaccines Containing a S177Q Point Mutation in the Central Conserved Domain of the RSV G Protein Improves Immunogenicity.Viral immunology · 2025Article
- Analyzing Differences in Viral Dynamics Between Vaccinated and Unvaccinated RSV Patients.Epidemiologia (Basel, Switzerland) · 2025Article
- Preventing RSV Infection in Children: Current Passive Immunizations and Vaccine Development.Pathogens (Basel, Switzerland) · 2025Review
- Interactions Between Bovine Respiratory Syncytial Virus and Cattle: Aspects of Pathogenesis and Immunity.Viruses · 2024Review
- Vaccines for Respiratory Viruses-COVID and Beyond.Vaccines · 2024Review
- Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is important to understand the features affecting virus replication, fitness, and transmissibility as they contribute to the outcome of infection and affect disease intervention approaches. Respiratory syncytial virus (RSV) is a major contributor to respiratory disease, particularly in the infant and elderly populations. Although first described over 60 years ago, there are no approved vaccines and there are limited specific antiviral treatments due in part to our incomplete understanding of the features affecting RSV replication, immunity, and disease. RSV studies have typically focused on using continuous cell lines and conventional RSV strains to establish vaccine development and various antiviral countermeasures. This review outlines how the RSV G protein influences viral features, including replication, transmission, and disease, and how understanding the role of the G protein can improve the understanding of preclinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.